Friday, 26 July 2013

Impact of Specific Glucose-Control Strategies on Microvascular and Macrovascular Outcomes in 58,000 Adults With Type 2 Diabetes

In a large representative cohort of adults with type 2 diabetes, more aggressive glucose-control strategies have mixed short-term effects on microvascular complications and do not reduce the myocardial infarction rate over 4 years of follow-up (Diabetes Care)

Biomarkers for type 2 diabetes and impaired fasting glucose using a non-targeted metabolomics approach

This T2D-IFG biomarker study has surveyed the broadest panel of non-targeted metabolites to date, revealing both novel and known associated metabolites and providing potential novel targets for clinical prediction and a deeper understanding of causal mechanisms (Diabetes)

Vipidia (alogliptin)

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Vipidia, 6.25 mg, 12.5 mg and 25 mg, film-coated tablet intended for the treatment of type 2 diabetes mellitus (European Medicines Agency)

Investigation into GLP-1 based diabetes therapies concluded

No new concerns for GLP-1 therapies identified on the basis of available evidence (European Medicines Agency)

No comments:

Post a Comment